NCT07315698

Brief Summary

Hysteroscopy is a procedure used to evaluate abnormalities within the uterus (intrauterine. Currently, hysteroscopy can be performed in an outpatient clinic setting according to established standards, known as office hysteroscopy. Although office hysteroscopy offers greater comfort compared with hysteroscopy performed in the operating room, the procedure can still cause pain for patients. At Dr. Cipto Mangunkusumo National General Hospital, one of the analgesics routinely used for office hysteroscopy is ketoprofen, a non-steroidal anti-inflammatory drug (NSAID) administered rectally. However, ketoprofen frequently causes uncomfortable side effects such as nausea, vomiting, and diarrhea, making alternative analgesics necessary-particularly for patients with contraindications to NSAIDs, including those with allergic reactions. In addition, rectal administration is less practical and less comfortable for patients compared with oral administration. Therefore, an alternative analgesic with fewer side effects and a more practical route of administration is needed for pain management during office hysteroscopy. Further evaluation is required to assess the efficacy of paracetamol compared with ketoprofen as an alternative analgesic for pain management in office hysteroscopy. Adequate pain management is expected to enhance the overall success of the procedure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2020

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2020

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
2.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 22, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 14, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 2, 2026

Completed
Last Updated

January 2, 2026

Status Verified

October 1, 2020

Enrollment Period

2.6 years

First QC Date

November 14, 2025

Last Update Submit

December 23, 2025

Conditions

Keywords

Office HysteroscopyGynecologic EndoscopyOutpatient ProcedureVisual Analogue ScaleNon-steroidal Anti-inflammatory DrugsWomen's HealthAnalgesic Efficacy

Outcome Measures

Primary Outcomes (1)

  • The Intensity of Pain During Office-Hysteroscopy Procedure

    The intensity of pain during office-hysteroscopy procedure, measured using a visual analogue scale when the hysteroscope entered the external cervical ostium

    During the office-hysteroscopy procedure

Secondary Outcomes (1)

  • Cramping Pain Score within 30 Minutes After Office-Hysteroscopy Procedure

    Within 30 minutes after office-hysteroscopy procedure

Study Arms (2)

Ketoprofen 100 mg orally for Office Hysteroscopy Pre-Medication

ACTIVE COMPARATOR

Ketoprofen 100 mg orally for office hysteroscopy procedure pre-medication 60 minutes before the procedure. Then, assessing the intensity of pain during the procedure and cramping within 30 minutes after the procedure.

Drug: Ketoprofen 100mg

Paracetamol 1000 mg orally for Office Hysteroscopy Pre-Medication

ACTIVE COMPARATOR

Paracetamol 1000 mg orally for office hysteroscopy procedure pre-medication 60 minutes before the procedure. Then, assessing the intensity of pain during the procedure and cramping within 30 minutes after the procedure.

Drug: Paracetamol 1000 Mg Oral Tablet

Interventions

Ketoprofen 100 mg orally for office hysteroscopy procedure pre-medication 60 minutes before the procedure. Then, assessing the intensity of pain during the procedure and cramping within 30 minutes after the procedure.

Also known as: Ketoprofen 100mg orally
Ketoprofen 100 mg orally for Office Hysteroscopy Pre-Medication

Paracetamol 1000 mg orally for office hysteroscopy procedure pre-medication 60 minutes before the procedure. Then, assessing the intensity of pain during the procedure and cramping within 30 minutes after the procedure.

Paracetamol 1000 mg orally for Office Hysteroscopy Pre-Medication

Eligibility Criteria

Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Women who underwent an office-hysteroscopy procedure
  • Not using analgesics one month before joining the study

You may not qualify if:

  • Women with a history of Asthma
  • Women with a history of Allergy to Paracetamol or NSAID class drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

RSCM Kintani

Jakarta Pusat, Jakarta Special Capital Region, 10430, Indonesia

Location

Related Publications (4)

  • Teran-Alonso MJ, De Santiago J, Usandizaga R, Zapardiel I. Evaluation of pain in office hysteroscopy with prior analgesic medication: a prospective randomized study. Eur J Obstet Gynecol Reprod Biol. 2014 Jul;178:123-7. doi: 10.1016/j.ejogrb.2014.04.030. Epub 2014 May 6.

    PMID: 24835860BACKGROUND
  • Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ. 1990 Feb 3;300(6720):278-84. doi: 10.1136/bmj.300.6720.278. No abstract available.

    PMID: 2106956BACKGROUND
  • Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol. 1999 Mar;13(2):119-22. doi: 10.1155/1999/361651.

    PMID: 10203429BACKGROUND
  • el Valle, C.; Solano, J.A.; Rodríguez, A.; Alonso, M. Pain management in outpatient hysteroscopy. Gynecol Minim Invasive Ther. 2016;5(4):141-7.

    BACKGROUND

MeSH Terms

Interventions

KetoprofenAcetaminophenTablets

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAcetanilidesAnilidesAmidesAniline CompoundsAminesDosage FormsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Gynecologic Oncology Division

Study Record Dates

First Submitted

November 14, 2025

First Posted

January 2, 2026

Study Start

November 1, 2020

Primary Completion

May 30, 2023

Study Completion

August 22, 2025

Last Updated

January 2, 2026

Record last verified: 2020-10

Data Sharing

IPD Sharing
Will not share

Locations